Daily coverage of equity markets, sectors, and major indices.
In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.
3,899 total articles
Zoetis stock climbed 3% after the company reported fourth-quarter adjusted EPS of $1.48, topping the LSEG consensus of $1.40. Management issued fiscal 2026 guidance with adjusted EPS of $7.00 to $7.10 and revenue guidance of $9.825 billion to $10.025 billion, both slightly ahead of Wall Street expectations. Some analysts highlighted that internatio…
CK Hutchison Holdings Ltd. has notified A.P. Moller-Maersk A/S that it will pursue legal remedies if Maersk’s terminal arm moves to operate the Balboa and Cristobal ports without CK Hutchison’s consent. The move follows Panama authorities' invalidation of CK Hutchison’s contract to run the two ports, and Panama has indicated APM Terminals would man…
Shares of Dell and HP declined sharply after Lenovo warned that disruptions in memory supply and rising prices could affect the global hardware industry for a full year. Lenovo reported a 21% drop in December-quarter net income while revenue increased to $22.2 billion. The company said memory costs rose 40% to 50% in the last quarter and contract p…
Futures tied to Canada’s primary stock index moved modestly higher Thursday as market participants parsed a stream of corporate earnings and waited on additional U.S. economic data. The S&P/TSX 60 futures climbed by 3 points (0.2%) as the broader S&P/TSX composite retreated slightly from an earlier intraday peak. Technology losses, led by Shopify a…
Exelon reported fourth-quarter adjusted earnings above analyst expectations and raised its four-year capital expenditure plan to $41.3 billion from $38 billion. The Chicago-based utility said higher electricity rates and accelerating power demand supported the results and that it expects 2026 adjusted earnings of $2.81 to $2.91 per share, slightly …
PG&E raised the lower bound of its full-year 2026 profit outlook, citing strong power demand driven by data centers and broader electrification. The utility has moved additional data center capacity into final engineering and reiterated major transmission spending plans, even as quarterly adjusted earnings missed analyst expectations and shares dip…
Wells Fargo’s 2026 biotech outlook narrows its high-conviction SMID-cap ideas to six companies it expects to outperform based on near-term clinical readouts, regulatory milestones, and commercial rollouts. The bank’s coverage spans 22 names, but Ionis, Beam, Taysha, Sarepta, Spyre and RAPT stand out for their pipeline depth, upcoming data, and fina…
Clear Street has reduced the valuation it is seeking in its U.S. initial public offering to $7.2 billion from an earlier $11.8 billion target. The New York-based brokerage is offering 13 million shares at $26 to $28 apiece, down from an initial plan to sell 23.8 million shares at $40 to $44 each. The offering is expected to price later on Thursday,…
Barclays upgraded Recordati from underweight to equal weight, citing an improved valuation and reduced structural overhang after a year of underperformance and signs that private-equity holder CVC is less likely to place additional shares at current prices. The bank maintained its €48 price target and adjusted forecasts to reflect Isturisa commerci…
WarrenAI's latest screening highlights four companies with exceptionally large EPS growth projections and sizeable analyst upside targets. Each stock pairs projected earnings strength with differing revenue trajectories and risk profiles, creating varied opportunities for investors focused on high-growth outcomes.
Shares of BioMarin and Ascendis fell about 6% after BridgeBio reported that its oral infigratinib met the primary endpoint in the Phase 3 PROPEL 3 trial, demonstrating superior annualized height velocity and a first statistically significant improvement in body proportionality versus placebo. BridgeBio reported no serious adverse events related to …
Morgan Stanley now projects global PC shipments will fall by more than 5% in 2026 after January notebook builds fell well below expectations. The bank's supply-chain checks showed the Top 5 notebook ODMs missed build targets by 14% in January, with Quanta reporting about a 30% shortfall. Morgan Stanley sees weaker consumer demand tied to higher mem…
Saudi Arabia's Tadawul All Share finished the session up 0.75%, supported by gains in Insurance, Energy & Utilities and Hotels & Tourism sectors. Saudi Kayan Petrochemical, Ataa Educational and Rabigh Refining were the top risers, while Saudia Dairy and Foodstuff fell to three-year lows. Oil and gold retreated modestly during the session.
U.S. equity futures rose Thursday as traders continued to process quarterly corporate results and the market implications of a robust monthly employment report. Several large-cap names moved notably in premarket trade after earnings releases and regulatory updates, with technology and consumer-facing stocks seeing mixed reactions.
Pilots and flight attendants staged coordinated industrial action at Germany’s largest carrier, prompting Lufthansa to cancel close to 800 flights and affecting roughly 100,000 passengers. German airport association ADV provided a lower estimate of cancellations and passenger impact. The stoppage comes as high-profile events begin in Berlin and Mun…
Seres Therapeutics said it will pause further investment in a planned Phase 2 trial of SER-155 and reduce its workforce by about 30%. The company finalized a protocol with the FDA but is pausing the study while it pursues funding. Seres expects the cost cuts to extend its cash runway through Q3 2026 and will concentrate on earlier-stage live biothe…
PBF Energy posted an adjusted fourth-quarter profit of $0.49 per share, beating expectations for a $0.10 per share loss, as refining margins strengthened amid tighter global fuel supplies and higher crude differentials. Consolidated gross refining margin more than doubled to $11.16 per barrel and throughput rose to 888,900 bpd. The company said rec…
Baxter signaled that its adjusted earnings per share for fiscal 2026 will land between $1.85 and $2.05, a range below the Wall Street consensus of $2.25. The medical products maker attributed the shortfall to ongoing effects from hurricane-related disruptions at a key manufacturing facility. The stock plunged about 14% in premarket trading after th…
BridgeBio Pharma reported positive topline results from its Phase 3 PROPEL 3 trial of oral infigratinib in achondroplasia, driving a 9% intraday gain in the company’s stock. The study met its primary endpoint for annualized height velocity at Week 52 and showed a statistically significant improvement in body proportionality in a pre-specified subgr…
Kepler Cheuvreux upgraded Banca Generali from Hold to Buy and raised its target price to €61.50 from €60 after the bank reported stronger-than-expected 2025 results. The broker cited robust fourth-quarter operating performance, revenue beats and management guidance for 2026 as the basis for higher earnings estimates and valuation assumptions, while…
Italian tax police carried out searches at Amazon's Milan headquarters, the residences of seven Amazon managers and the offices of auditing firm KPMG as part of a new strand of a tax evasion investigation. Authorities are probing whether Amazon maintained an undisclosed, permanent establishment in Italy between 2019 and 2024 and therefore should ha…
ICON plc's stock plunged after the company disclosed an internal accounting investigation focused on revenue recognition from 2023 through 2025. The probe has prompted a delay in fourth-quarter and full-year 2025 results, withdrawal of 2025 guidance, and an expected report of material weaknesses in internal controls over financial reporting.
The FTSE 100 climbed to a fresh record midday, supported by a sharp rise in Schroders after the British fund manager accepted a £9.9 billion all-cash offer from U.S. asset manager Nuveen. Broader European markets advanced and the pound strengthened slightly versus the dollar. Official data showed the U.K. economy expanded by a marginal 0.1% in Dece…
Jefferies has shifted its rating on Novo Nordisk to Hold from Underperform after steep cuts to consensus forecasts and a repricing of the stock. The broker lifted its price target to 275 Danish crowns from 270, saying headline pricing pressures and margin concerns have been reflected in consensus estimates. While the U.S. oral Wegovy launch could p…
Viking Therapeutics saw its stock jump 11.63% following an announcement that its investigational oral obesity drug VK2735 will advance into late-stage trials in the third quarter of this year. The company cited late-stage study results showing once-daily oral dosing produced up to 12.2% average weight loss after 13 weeks and emphasized that offerin…
